Karim Fizazi

Karim Fizazi

UNVERIFIED PROFILE

Are you Karim Fizazi?   Register this Author

Register author
Karim Fizazi

Karim Fizazi

Publications by authors named "Karim Fizazi"

Are you Karim Fizazi?   Register this Author

100Publications

4598Reads

29Profile Views

Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.

Eur Urol 2020 Apr 27;77(4):508-547. Epub 2020 Jan 27.

University of Bern, Bern, Switzerland; Department of Medical Oncology and Haematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2020.01.012DOI Listing
April 2020

Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: Natural history, management and outcome.

Eur J Cancer 2020 Apr 6;129:117-122. Epub 2020 Mar 6.

Gustave Roussy, Université Paris-Saclay, Oncology Medicine Department, Villejuif, F-94805, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2020.01.017DOI Listing
April 2020

The role of site-specific therapy for cancers of unknown of primary: A meta-analysis.

Eur J Cancer 2020 Mar 30;127:118-122. Epub 2020 Jan 30.

University of Ioannina, Ioannina, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.12.016DOI Listing
March 2020

ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer.

Eur Urol Focus 2020 Jan 5;6(1):63-70. Epub 2018 Sep 5.

Drug Development Department (DITEP), Inserm Unit U981, Université Paris Saclay, Université Paris-Sud, Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2018.08.022DOI Listing
January 2020

Impact of progression at baseline and on-treatment progression events in three large prostate cancer trials.

Eur J Cancer 2020 Jan 11;125:142-152. Epub 2019 Dec 11.

Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.10.029DOI Listing
January 2020

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.

N Engl J Med 2019 12 30;381(26):2506-2518. Epub 2019 Sep 30.

From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.); the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.); Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne-Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d'Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) - all in France; Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.); the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) - both in Germany; the Medical University of Vienna, Vienna (G.K.); Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.); Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona (J.C.); Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome - both in Italy (R.I.); Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.); Landspitali University Hospital, Reykjavik, Iceland (Á.S.); Sanofi, Global Medical Oncology, Cambridge, MA (A.O.); and 12 de Octubre University Hospital, Madrid (D.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1911206DOI Listing
December 2019

[Management of metastatic testicular germ cell tumors].

Bull Cancer 2019 Oct 26;106(10):896-902. Epub 2019 Aug 26.

Université Paris-Saclay, Gustave-Roussy, Department of Cancer Medicine, 114, rue Edouard-Vaillant, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.05.004DOI Listing
October 2019

A Case of Heavily Pretreated Metastatic Germ Cell Tumor With Ongoing Long-term Complete Response After Gemcitabine Treatment.

Clin Genitourin Cancer 2019 06 26;17(3):e485-e487. Epub 2019 Jan 26.

Department of Cancer Medicine, Gustave Roussy, Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.01.010DOI Listing
June 2019

Abiraterone in metastatic castration-resistant prostate cancer: Efficacy and safety in unselected patients.

Cancer Treat Res Commun 2018 16;17:37-42. Epub 2018 Oct 16.

Department of Cancer Medicine, Hôpital Saint Louis, Paris, France. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S24682942183005
Publisher Site
http://dx.doi.org/10.1016/j.ctarc.2018.10.001DOI Listing
May 2019

Fatigue and physical activity in cancer survivors: A cross-sectional population-based study.

Cancer Med 2019 05 12;8(5):2535-2544. Epub 2019 Mar 12.

Department of Medical Oncology, Gustave Roussy, Université Paris-Sud, Université Paris-Saclay, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.2060DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536944PMC
May 2019

The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer.

Drugs 2019 Mar;79(4):381-400

Department of Clinical Medicine and Surgery, University Federico II of Naples, Via Pansini 5, 80131, Naples, Italy.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40265-019-1060-5
Publisher Site
http://dx.doi.org/10.1007/s40265-019-1060-5DOI Listing
March 2019

Overview of Systemic Therapy Augmenting Management of High-risk Localized Prostate Cancer.

Eur Urol Focus 2019 03 8;5(2):168-170. Epub 2019 Feb 8.

Department of Cancer Medicine, Gustave Roussy, University of Paris Sud, Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2019.01.015DOI Listing
March 2019

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.

N Engl J Med 2019 03 14;380(13):1235-1246. Epub 2019 Feb 14.

From Institut Gustave Roussy, Université Paris-Sud, Villejuif, France (K.F.); Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); Tampere University Hospital and University of Tampere, Tampere (T.L.T.), and Orion Pharma, Orion Corporation, Espoo (A.S., T.S.) - all in Finland; National Cancer Institute, Vilnius (A.U.), and Medical Academy, Lithuanian University of Health Sciences, Kaunas (M.J.) - both in Lithuania; Stradins Clinical University Hospital, Riga, Latvia (E.V.); N.N. Alexandrov National Cancer Center of Belarus, Minsk, Belarus (S.P.); Hospital Erasto Gaertner, Curitiba, Brazil (M.L.); National Medical Research Radiological Center, Ministry of Health of the Russian Federation, Moscow (B.A.); Bayer, Berlin (I.K., C.K.); and Massachusetts General Hospital Cancer Center, Boston (M.R.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1815671DOI Listing
March 2019

Managing Nonmetastatic Castration-resistant Prostate Cancer.

Eur Urol 2019 02 14;75(2):285-293. Epub 2018 Aug 14.

The Royal Marsden Hospital and The Institute of Cancer Research, London, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.07.035DOI Listing
February 2019

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.

Eur Urol 2019 01 16;75(1):88-99. Epub 2018 Apr 16.

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, School of Medicine, Baltimore, MD, USA; Department of Urology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, School of Medicine, Baltimore, MD, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.03.028DOI Listing
January 2019

Advancing therapies in metastatic castration-resistant prostate cancer.

Expert Opin Pharmacother 2018 11 12;19(16):1797-1804. Epub 2018 Oct 12.

a Department of Medical Oncology , Institut Gustave Roussy, University of Paris Sud , Villejuif , France.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14656566.2018.1
Publisher Site
http://dx.doi.org/10.1080/14656566.2018.1527312DOI Listing
November 2018

Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials.

Eur Urol Oncol 2018 Nov 30. Epub 2018 Nov 30.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2018.11.006DOI Listing
November 2018

Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.

Clin Genitourin Cancer 2018 10 24;16(5):332-340. Epub 2018 Jul 24.

Cliniques Universitaires Saint-Luc Université Catholique de Louvain Brussels, Woluwe-Saint-Lambert, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.07.017DOI Listing
October 2018

Treatment of hormone-naïve metastatic prostate cancer.

Curr Opin Support Palliat Care 2018 09;12(3):334-338

Département De Médecine Oncologique, Institut Gustave Roussy, Université Paris-Saclay, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/SPC.0000000000000359DOI Listing
September 2018

Reply to C. Ren et al.

J Clin Oncol 2018 08 12;36(22):2354-2356. Epub 2018 Jun 12.

Glenn Heller, Memorial Sloan Kettering Cancer Center, New York, NY; Robert McCormack and Thian Kheoh, Janssen Research & Development, Raritan, NJ; Arturo Molina, Janssen Research & Development, Los Angeles, CA; Matthew R. Smith, Massachusetts General Hospital, Boston, MA; Robert Dreicer, University of Virginia Medical School, Charlottesville, VA; Fred Saad, University of Montreal, Montreal, Quebec, Canada; Ronald de Wit, Erasmus Medical Center, Rotterdam, Netherlands; Dana T. Aftab, Exelixis, South San Francisco, CA; Mohammed Hirmand, Medivation, San Francisco, CA; Ana Limon-Carrera, Takeda Oncology, Cambridge, MA; Karim Fizazi, Institut Gustave Roussy, Villejuif, and University of Paris Sud, Orsay, France; Martin Fleisher, Memorial Sloan Kettering Cancer Center, New York, NY; Johann S. de Bono, The Institute of Cancer Research, and The Royal Marsden Hospital, Sutton, Surrey, United Kingdom; and Howard I. Scher, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.2672DOI Listing
August 2018

Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients.

J Immunother Cancer 2017 18;5:31. Epub 2017 Apr 18.

Institut Gustave Roussy, University of Paris-Sud, Department of Cancer Medicine, 114 Rue Edouard Vaillant, 94800 Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-017-0232-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394619PMC
June 2018

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.

N Engl J Med 2018 Jun;378(26):2465-2474

From the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago (M.H.), and Astellas Pharma, Northbrook (D.P., A.K.) - both in Illinois; Institut Gustave Roussy, University of Paris Sud, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.); Herlev Hospital, Herlev, Denmark (P.R.); Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); State University of Campinas (Unicamp), Campinas, Brazil (U.F.); Kiev City Clinical Hospital 3, Kiev, Ukraine (P.I.); Pfizer, San Francisco (E.D., K.M.); and the Department of Medical Oncology, San Camillo Forlanini Hospital, Rome (C.N.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1800536DOI Listing
June 2018

Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials.

J Clin Oncol 2018 02 22;36(6):572-580. Epub 2017 Dec 22.

Glenn Heller, Martin Fleisher, and Howard I. Scher, Memorial Sloan Kettering Cancer Center; Howard I. Scher, Weill Cornell Medical College, New York, NY; Robert McCormack, Janssen Research & Development, Raritan, NJ; Thian Kheoh and Arturo Molina, Janssen Research & Development, Los Angeles; Dana T. Aftab, Exelixis, South San Francisco; Mohammad Hirmand, Medivation, San Francisco, CA; Matthew R. Smith, Massachusetts General Hospital, Boston; Ana Limon, Takeda Oncology, Cambridge, MA; Robert Dreicer, University of Virginia Medical School, Charlottesville, VA; Fred Saad, University of Montreal, Montreal, Quebec, Canada; Ronald de Wit, Erasmus Medical Center, Rotterdam, the Netherlands; Karim Fizazi, Institut Gustave Roussy, Villejuif, and University of Paris Sud, Orsay, France; and Johann S. de Bono, The Institute of Cancer Research, and The Royal Marsden Hospital, Sutton, Surrey, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.2998DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815402PMC
February 2018

Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy.

Clin Genitourin Cancer 2017 12 12;15(6):e1081-e1088. Epub 2017 Aug 12.

Department of Medical Oncology, Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2017.07.015DOI Listing
December 2017

Treatment of Castration-naive Metastatic Prostate Cancer.

Eur Urol Focus 2017 12 27;3(6):518-521. Epub 2018 Feb 27.

Institut Gustave Roussy, Département de Médecine Oncologique, Université Paris-Saclay, Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S24054569183003
Publisher Site
http://dx.doi.org/10.1016/j.euf.2018.02.004DOI Listing
December 2017

Radiation therapy to the primary in metastatic prostate cancer: palliation only or altering tumor biology?

Curr Opin Urol 2017 Nov;27(6):580-586

aDepartment of Radiotherapy, Gustave Roussy, Université Paris-Sud bDepartment of Cancer Medicine, Gustave Roussy, Université Paris-Sud, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOU.0000000000000444DOI Listing
November 2017

Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm.

J Clin Oncol 2017 11 30;35(31):3525-3528. Epub 2017 Aug 30.

Torgrim Tandstad, St Olavs University Hospital, Trondheim, Norway; Christian K. Kollmannsberger, University of British Columbia, Vancouver, British Columbia, Canada; Bruce J. Roth, Washington University School of Medicine, St Louis, MO; Claudio Jeldres, Sherbrooke University, Sherbrooke, Quebec, Canada; Silke Gillessen, Kantonsspital, St Gallen, Switzerland; Karim Fizazi, University of Paris Sud, Paris, France; Siamak Daneshmand, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA; William T. Lowrance, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Nasser H. Hanna, Indiana University School of Medicine, Indianapolis, IN; Gabriella Cohn Cedermark, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden; Darren R. Feldman, Memorial Sloan Kettering Cancer Center and Weill Medical Cornell Medical College, New York, NY; Thomas Powles, Barts Cancer Institute, St Bartholomew's Hospital, Queen Mary University of London, London, United Kingdom; Mark A. Lewis, Intermountain Health, Salt Lake City, UT; Peter Scott Grimison, University of Sydney, Sydney, New South Wales, Australia; Douglas Bank, Testicular Cancer Resource Center, Riverwoods, IL; Christopher Porter, Virginia Mason Medical Center, Seattle, WA; Peter Albers, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany; Maria De Santis, Cancer Research Center, University of Warwick, Coventry, United Kingdom; Sandy Srinivas, Stanford University School of Medicine, Stanford, CA; George J. Bosl, Memorial Sloan Kettering Cancer Center, New York, NY; and Craig R. Nichols, Precision Genomics Cancer Research Clinic, Intermountain Health, Salt Lake City, UT; Testicular Cancer Commons, Portland, OR.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.4723DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791831PMC
November 2017

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.

J Clin Oncol 2017 Oct 28;35(28):3189-3197. Epub 2017 Jul 28.

Stéphane Oudard, Georges Pompidou European Hospital, Rene Descartes University; Mustapha Chadjaa; Sanofi, Paris; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif; Antoine Thiery-Vuillemin, Centre Hospitalier Universitaire Minjoz Besançon, Besançon, France; Lisa Sengeløv, Herlev Hospital, Herlev; Gedske Daugaard, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Steinbjørn Hansen, Odense University Hospital, Odense, Denmark; Fred Saad, Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada; Marie Hjälm-Eriksson, Karolinska University Hospital, Stockholm, Sweden; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Orazio Caffo, Santa Chiara Hospital, Trento, Italy; Daniel Castellano, University Hospital 12 de Octubre, Madrid, Spain; Paul N. Mainwaring, Icon Cancer Care, Brisbane, Queensland, Australia; John Bernard, Sanofi, Cambridge, MA; Liji Shen, Sanofi, Bridgewater, NJ; and Oliver Sartor, Tulane Cancer Center, New Orleans, LA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.72.1068DOI Listing
October 2017

Abiraterone in Metastatic Prostate Cancer.

N Engl J Med 2017 10 26;377(17):1697-8. Epub 2017 Oct 26.

BC Cancer Agency, Vancouver, BC, Canada

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1711029DOI Listing
October 2017

Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.

J Clin Oncol 2017 09 10;35(27):3097-3104. Epub 2017 Aug 10.

Wanling Xie, Meredith M. Regan, and Christopher J. Sweeney, Dana-Farber Cancer Institute, Boston, MA; Marc Buyse, International Drug Development Institute; Bertrand Tombal, Université Catholique de Louvain, Louvain-la-Neuve; Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Susan Halabi, Duke University Medical Center, Durham, NC; Philip W. Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY; Oliver Sartor, Tulane Medical School, New Orleans, LA; Howard Soule, Prostate Cancer Foundation, Santa Monica; Howard M. Sandler, Cedars-Sinai Medical Center, Los Angeles, CA; Noel W. Clarke, The Christie NHS Foundation Trust, Manchester; Matthew R. Sydes, University College London, London, United Kingdom; James J. Dignam, University of Chicago, Chicago, IL; Karim Fizazi, Institut Gustave-Roussy, Villejuif, France; Wendy R. Paruleker, Canadian Cancer Trials Group, Kingston, Ontario, Canada; and Scott G. Williams, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.9987DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652387PMC
September 2017

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.

N Engl J Med 2017 07 4;377(4):352-360. Epub 2017 Jun 4.

From Gustave Roussy, University of Paris Sud, Villejuif, France (K.F.); Janssen Research and Development, Los Angeles (N.T.), Beerse, Belgium (P.D.P.), San Diego, CA (T.K.), and Raritan, NJ (Y.C.P.); Instituto de Oncologia de Rosário, Rosário, Argentina (L.F.); National Cancer Center Hospital East, Chiba, Japan (N.M.); 12 de Octubre University Hospital, Madrid (A.R.-A.); P.A. Hertsen Moscow Cancer Research Institute, Moscow (B.Y.A.); Cerrahpaşa Medical Faculty, Istanbul University, Istanbul, Turkey (M.Ö.); Fudan University Shanghai Cancer Center, Shanghai, China (D.Y.); Studienpraxis Urologie, Nürtingen, Germany (S.F.); Oxford University Hospitals Foundation NHS Trust, Oxford, United Kingdom (A.P.); Janssen Global Services, Raritan, NJ (M.B.T.); and BC Cancer Agency, Vancouver, Canada (K.N.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1704174DOI Listing
July 2017

Clinical News.

Br J Hosp Med (Lond) 2017 Jul;78(7):368-371

Head, Department of Cancer Medicine Gustave Roussy, University of Paris-Sud, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12968/hmed.2017.78.7.368DOI Listing
July 2017

A Statistical Approach to Determine the Optimal Duration of Post-Treatment Follow-Up: Application to Metastatic Nonseminomatous Germ Cell Tumors.

Clin Genitourin Cancer 2017 04 8;15(2):230-236. Epub 2016 Aug 8.

Bureau des Essais Cliniques, Institut Claudius Regaud, Institut Universitaire du Cancer, Toulouse - Oncopole, Toulouse, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2016.07.023DOI Listing
April 2017

Burned-Out Testis Tumors in Asymptomatic Infertile Men: Multiparametric Sonography and MRI Findings.

J Ultrasound Med 2017 Apr 3;36(4):821-831. Epub 2016 Dec 3.

Department of Adult Radiology, Necker University Hospital, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7863/ultra.15.08037DOI Listing
April 2017

Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.

J Clin Oncol 2017 Jan 31;35(1):40-47. Epub 2016 Oct 31.

Tomasz M. Beer, Oregon Health and Science University, Portland, OR; Eugene D. Kwon, Mayo Clinic, Rochester, MN; Charles G. Drake, Johns Hopkins University, Baltimore, MD; Karim Fizazi, University of Paris-Sud, Villejuif; Gwenaelle Gravis, Institut Paoli-Calmettes, Marseille, France; Christopher Logothetis, University of Texas MD Anderson Cancer Center, Houston, TX; Vinod Ganju, Monash University, Melbourne, Victoria; Siobhan S. Ng, St John of God Hospital, Subiaco, Western Australia; Francis X. Parnis, Adelaide Cancer Centre, Adelaide, South Australia, Australia; Jonathan Polikoff, Southern California Permanente Medical Group, San Marcos, CA; Fred Saad, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada; Piotr Humanski, Niepubliczny Zaklad Opieki Zdrowotnej Specjalista, Kutno, Poland; Josep M. Piulats, Institut Català d'Oncologia, Barcelona; Javier Puente, Hospital Clínico San Carlos, Madrid, Spain; Pablo Gonzalez Mella, Instituto Oncologico, Viña del Mar; Pablo Gonzalez Mella, Fundación Arturo Lopez Pérez, Santiago, Chile; Dirk Jaeger, University Hospital, Heidelberg, Germany; Fabio A. Franke, Hospital de Caridade de Ijuí, Ijuí, Brazil; Roman Carvajal, Hospital Regional Valentin Gomez Farias, Zapopan, Mexico; Lisa Sengeløv, Herlev Hospital, Herlev, Denmark; M. Brent McHenry, Bristol-Myers Squibb, Wallingford, CT; Arvind Varma, DOCS Inc, New York, NY; Alfonsus J. van den Eertwegh, VU University Medical Center, Amsterdam; and Winald Gerritsen, Radboud University, Nijmegen, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.1584DOI Listing
January 2017

Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours.

Eur J Cancer 2016 12 4;69:151-157. Epub 2016 Nov 4.

Department of Cancer Medicine, Institut Gustave Roussy, Université Paris-Sud, 94800 Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.10.003DOI Listing
December 2016

Optimal Treatment Sequence for Metastatic Castration-resistant Prostate Cancer.

Eur Urol Focus 2016 Dec 23;2(5):488-498. Epub 2016 Nov 23.

Prostate Cancer Targeted Therapy Group, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2016.10.008DOI Listing
December 2016

Bone Scan Index and Progression-free Survival Data for Progressive Metastatic Castration-resistant Prostate Cancer Patients Who Received ODM-201 in the ARADES Multicentre Study.

Eur Urol Focus 2016 Dec 3;2(5):547-552. Epub 2016 Feb 3.

Department of Translational Medicine Division of Urological Cancers, Malmö, Lund University, Sweden; Department of Urology, Skåne University Hospital, Malmö, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2016.01.005DOI Listing
December 2016

Biennial report on genitourinary cancers.

Authors:
Karim Fizazi

Eur J Cancer 2016 10 26;66:125-30. Epub 2016 Aug 26.

Department of Cancer Medicine, Gustave Roussy, University Paris Sud, 94800 Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.06.026DOI Listing
October 2016

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.

J Clin Oncol 2016 09 11;34(25):3005-13. Epub 2016 Jul 11.

Matthew Smith, Massachusetts General Hospital, Boston, MA; Johann De Bono, Royal Marsden Hospital, Sutton; Syed Hussain, University of Liverpool, Liverpool, United Kingdom; Cora Sternberg, San Camillo and Forlanini Hospitals, Rome; Ugo De Giorgi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori-Istituto di Ricovero e Cura a Carattere Scientifico, Meldola; Giorgio Cruciani, Istituto Tumori Romagna, Lugo di Romagna, Italy; Sylvestre Le Moulec, Hôpital d'Instruction des Armées Val-de-Grâce; Stéphane Oudard, European Hospital Georges Pompidou and Paris Descartes University, Paris; Antoine Thiery-Vuillemin, Jean Minjoz Hospital, Besançon; Nadine Houédé, Institut de Cancérologie du Gard-Centre Hospitalier Universitaire Caremeau, Nîmes; Karim Fizazi, Institute Gustave Roussy, University of Paris Sud, Villejuif, France; Michael Krainer, Medical University of Vienna, Vienna, Austria; Andries Bergman, Netherlands Cancer Institute, Amsterdam; Ronald De Wit, Erasmus University Medical Center and Cancer Institute, Rotterdam, the Netherlands; Wolfgang Hoelzer, Praxis für Urologie; Kurt Miller, Charité-Universitätsmedizin Berlin, Berlin; Martin Bögemann, University of Muenster Medical Center, Muenster; Susan Feyerabend, Studienpraxis Urologie, Nürtingen; Arnulf Stenzl, University Hospital, Tübingen, Germany; Fred Saad, Centre Hospitalier de I'Université de Montréal, Montreal, Quebec, Canada; Elaine Lam, University of Colorado Anschutz Medical Campus, Aurora, CO; Jonathan Polikoff, Kaiser Permanente Medical Group, San Diego; David Ramies, Colin Hessel, and Aaron Weitzman, Exelixis, South San Francisco, CA; and Paul Mainwaring, Hematology and Oncology Clinics of Australia, Brisbane, Queensland, Australia.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/34/25/3005.full.pdf
Web Search
http://dx.doi.org/10.1200/JCO.2015.65.5597DOI Listing
September 2016

Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors.

Gynecol Oncol 2016 09 8;142(3):452-7. Epub 2016 Jul 8.

Department of Cancer Medicine, Institut Gustave-Roussy, 114 rue Edouard Vaillant, F-94805 Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2016.07.005DOI Listing
September 2016

Safety of available treatment options for renal cell carcinoma.

Expert Opin Drug Saf 2016 Aug 23;15(8):1097-106. Epub 2016 May 23.

a Gustave Roussy Cancer Campus.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14740338.2016.1184643DOI Listing
August 2016

Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors.

Eur J Cancer 2016 07 3;61:44-51. Epub 2016 May 3.

Department of Cancer Medicine, Gustave Roussy, Cancer Campus, Grand Paris, University of Paris-Sud, Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.03.070DOI Listing
July 2016

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.

J Clin Oncol 2016 05 7;34(14):1652-9. Epub 2016 Mar 7.

Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.65.7270
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.65.7270DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872320PMC
May 2016

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

J Clin Oncol 2016 Apr 22;34(12):1402-18. Epub 2016 Feb 22.

Howard I. Scher, Michael J. Morris, Dana E. Rathkopf, and Susan F. Slovin, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College; David Nanus, NewYork Presbyterian Weill Cornell Medical Center; Lawrence W. Schwartz, NewYork Presbyterian Columbia University Medical Center, New York, NY; Walter M. Stadler, University of Chicago Medicine, Chicago, IL; Celestina Higano and Peter S. Nelson, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA; Ethan Basch, University of North Carolina at Chapel Hill, Chapel Hill, NC; Emmanual S. Antonarakis and Michael A. Carducci, Johns Hopkins University School of Medicine, Baltimore, MD; Tomasz M. Beer, Oregon Health and Science University, Portland, OR; Paul G. Corn and Christopher Logothetis, MD Anderson Cancer Center, Houston, TX; Robert Dreicer, University of Virginia School of Medicine, Charlottesville, VA; Daniel J. George, Susan Halabi, and Andrew J. Armstrong, Duke University and Duke Cancer Institute, Durham, NC; Elisabeth I. Heath, Wayne State University Karmanos Cancer Institute, Detroit; and Maha Hussain, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Wm. Kevin Kelly, Sidney Kimmel School of Medicine at Thomas Jefferson University, Philadelphia, PA; Glenn Liu and George Wilding, University of Wisconsin Carbone Cancer Center, Madison, WI; Mark N. Stein, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ; Charles S. Ryan and Eric J. Small, University of California Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Oliver Sartor, Tulane School of Medicine, New Orleans, LA; Matthew Raymond Smith, Massachusetts General Hospital Cancer Center and Harvard Medical School; Mary-Ellen Taplin and Philip W. Kantoff, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, Franc

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.2702DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872347PMC
April 2016